Carboplatin-oral etoposide personalised dosing in elderly non-small cell lung cancer patients

G. Frasci, P. Comella, N. Panza, G. De Cataldis, F. Del Gaizo, C. Pozzo, A. Gravina, P. Ruffolo, R. Cioffi, P. Marcatili, M. Della Vittoria, S. Monfardini, G. Comella

Research output: Contribution to journalArticle

Abstract

The toxicity and therapeutic activity, including the effect on quality of life, of the carboplatin-oral etoposide combination, given with an intrapatient dose escalation, was tested in 38 non-small cell lung cancer (NSCLC) patients aged over 70 years, and in 8 younger patients with a performance status of 2. In the absence of grade 3-4 toxicity, doses were escalated as follows: first course (carboplatin AUC 4; etoposide 50 mg twice daily orally days 1-14); second course (carboplatin AUC 5; etoposide 50 mg twice daily orally days 1-14); third course (carboplatin AUC 5; etoposide 50 mg twice daily orally days 1-21). A total of 141 chemotherapy cycles were delivered. The treatment was, in general, well tolerated and no toxic deaths occurred. More than 60% of patients received 100% of the planned dose intensity. Transient grade 4 neutropenia or thrombocytopenia occurred in 6 and 2 patients, respectively, but only 2 patients had to be hospitalised because of fever. All patients were evaluated for activity on an 'intention to treat basis'. Ten partial responses and 20 stable disease were recorded, for an overall response rate of 22% (95% confidence interval (CI) = 11-36). 9/38 (24%; 95% CI = 12-41) elderly patients obtained a partial response. The median response duration was 4 months. A quality of life improvement was observed in 19 of the 46 enrolled patients (41%; 95% CI = 27-57), and 15/46 (33%; 95% CI = 1948) showed a performance status improvement. The quality of life score improved in 17/38 (45%) elderly patients. 8/10 responders and 11/20 patients with stable disease showed a concomitant improvement in quality of life. At a median potential follow-up of 16 months (range 2-21), 31 patients had had progression of disease and 23 had died, for a median time to progression (TTP) and overall survival (OS) of 5 and 10 months, respectively. The median survival time was 11 months in elderly patients. The median time to subjective impairment (TSI) was 6 months (7 months in the elderly group). One-year estimated TTP, TSI and OS rates were 22, 29 and 41%, respectively. At multivariate Cox analysis, a > 25% improvement in the quality of life score was more predictive of a better survival outcome than the response achievement.

Original languageEnglish
Pages (from-to)1710-1714
Number of pages5
JournalEuropean Journal of Cancer
Volume34
Issue number11
DOIs
Publication statusPublished - Oct 1998

Keywords

  • Carboplatin
  • Daily administration
  • Elderly
  • Non-small cell lung cancer
  • Oral etoposide
  • Poor performance status

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Carboplatin-oral etoposide personalised dosing in elderly non-small cell lung cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Frasci, G., Comella, P., Panza, N., De Cataldis, G., Del Gaizo, F., Pozzo, C., Gravina, A., Ruffolo, P., Cioffi, R., Marcatili, P., Della Vittoria, M., Monfardini, S., & Comella, G. (1998). Carboplatin-oral etoposide personalised dosing in elderly non-small cell lung cancer patients. European Journal of Cancer, 34(11), 1710-1714. https://doi.org/10.1016/S0959-8049(98)00207-X